Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference Call

• Medicure Inc. reported Q1 2026 financial results showing total net revenue of $7.9 million, up from $5.4 million in Q1 2025.
• Adjusted EBITDA improved significantly to a positive $280,000 compared to $28,000 in the prior year period.
• Net loss narrowed to $406,000 ($0.04 per share) from $694,000 ($0.07 per share) in Q1 2025.
• ZYPITAMAG® revenue increased to $2.3 million, driven by traditional insured channels and Marley Drug sales.
• AGGRASTAT® revenue declined to $979,000 due to generic competition from tirofiban.
• Pharmacy Business Segment revenue grew to $5.7 million, supported by acquisitions Gateway Medical Pharmacy and West Olympia Pharmacy.
• Unrestricted cash decreased to $1.5 million at March 31, 2026, down from $3.8 million at December 31, 2025.

• The operational improvement in Adjusted EBITDA turning positive is a material step forward compared to the negative EBITDA reported in FY 2025 and Q3 2025.
• Revenue growth confirms the efficacy of the pharmacy acquisition strategy announced in previous quarters, validating management's long-term value creation thesis.
• However, the cash position deterioration from $3.8 million to $1.5 million in a single quarter represents a significant liquidity risk that was already flagged in FY 2025 results but has accelerated.
• The net loss narrowing is consistent with expectations following the acquisition ramp-up, making it incremental rather than a surprise market mover.
• No new strategic investors or major capital raises were announced in this release, leaving the cash runway uncertainty unresolved for the immediate future.

• Medicure Inc. operates a diversified platform combining pharmaceutical manufacturing and pharmacy services.
• Flagship products include ZYPITAMAG® (pain management) and AGGRASTAT® (antiplatelet therapy).
• The company has pivoted towards growth via acquisitions, specifically Gateway Medical Pharmacy and West Olympia Pharmacy, to diversify revenue streams beyond proprietary drugs.
• R&D focus is currently on MC-1 for PNPO deficiency, a Phase 3 trial requiring significant capital expenditure.